Kornimate/medical-research-clean huggingface dataset:
investigation of the efficacy of fistula obliteration by steam ablation in peri̇anal fistulas

Conditions: Anal Fistula

Summary: perianal fistula(pf) is one of the most frequent disease in anorectal disease.the incidence of pf is 8,6 -10 / 100 000 . the first surgical treatment is defined by hippocrates in pf .this surgical treatment which found by hippocrates , involves seton insertion into the tract of fistula . today most of surgeon still use the same technic but pf is really hard disease to treat. recurrence rate of pf is really high and there are lots of complication about this disease. the most scary complication during the surgery or postoperatively is anal disfunction. ın pf surgical technics involves ;fistulectomy (coring out), lay open (fistulotomy), ligation of intersphincteric fistula tract, advancement flap and laser ablation of the fistula tract . the popularity of laser ablation of the fistula tract is increasing day by day.this surgical procedure is applied with the laser device which use in varicose vain ablation in vascular surgery.in this study the investigator are trying to find out the effect of steam ablation in pf on rats.

perianal fistula(pf) is one of the most frequent disease in anorectal disease..this surgical treatment which found by hippocrates , involves seton insertion into the tract of fistula . todaymost of surgeon still use the same technic but pf is really hard disease to treat. recurrence rate of pf is really high and there are lots of complication about this disease. the most scary complication during the surgery or postoperatively is anal disfunction. ın pf surgical technics involves ;fistulectomy (coring out), lay open (fistulotomy), ligation of intersphincteric fistula tract), advancement flap and laser ablation of the fistula tract . the popularity of laser ablation of the fistula tract is increasing day by day.this surgical procedure is applied with the laser device which use in varicose vain ablation in vascular surgery.in this study the investigator are trying to find out the effect of steam ablation in pf on rats.this new procedure has to be tried on rat firstly and the studies is very important which tried on rats. our research includes 32 rats and firstly the investigator created perianal fistula tract with 2.0 silk suture material on 3 o'clock in perianal region.1 month will wait for the maturation of fistula tract. after that the suture materials removed from the fistula tract and one fistula tract will treat with steam ablation device (3 o'clock )in 16 rats and the other 16 rats will be the control group .1 month will be wait for the examination of treatment of fistula tract in steam ablation group.evaluation of fistula tract will define with microscopic examination after the excision.end of the study the investigator will be find out the effect of steam ablation on perianal fistula .

Eligibility criteria:
inclusion criteria: * all rats which have iatrogenic perianal fistula tract. exclusion criteria: * death of rat

Keywords: anal fistula steam ablation rat
prediction of atherosclerotic plaque progression

Conditions: Coronary Artery Disease

Summary: to predict coronary atherosclerosis progression in patients with acute coronary syndrome by the use of intracoronary imaging methods. to investigate the ability of nirs to detect vulnerable plaque characterized by the presence of oct-defined tcfa to study the influence of gene polymorphisms (in genes playing role in vessel dilatation) on the progression of coronary atherosclerosis and clinical outcomes

the fundamental aim of this study is to investigate the ability of intracoronary imaging to predict progression of coronary atherosclerosis in patients with acute coronary syndrome. in patients who are indicated for acute coronary angiography and have at least one non-culprit lesion (not indicated for revascularization) identical segment of non-culprit vessel will be analysed and several parameters will be detected by oct (optical coherence tomography) and nirs (near-infrared spectroscopy) including the presence of tcfa (thin-cap fibroatheroma) and plaque lipid content quantified by lcbi (lipid core burden index). during follow up visits (1y, 2y, 5y and 10y) major cardiovascular events will be monitored and the progression of coronary involvement will be estimated at 1y and 2y by ccta (coronary computed angiography). the second part of the trial is to investigate the ability of nirs to detect vulnerable plaque characterized by the presence of oct-defined tcfa. a further target is to study the influence of gene polymorphisms (in genes playing a role in vessel dilatation) on the progression of coronary atherosclerosis and clinical outcomes. patient dna will be isolated from peripheral blood leucocytes, and polymorphisms in genes for hemoxygenase-1 and endothelial nitric oxide synthase will be analysed.

Eligibility criteria:
inclusion criteria: * acute coronary syndrome diagnosis * presence of at least one non-culprit coronary lesion (not indicated for revascularisation) exclusion criteria: * contraindication for oct or ivus * circulatory instability * renal insufficiency (creatinine level \>200umol/l) * pregnant or of childbirth age and not using reliable contraception * life expectancy of less than one year
adoptive transfer of specific hcc antigens cd8+ t cells for treating patients with relapsed/advanced hcc

Conditions: Hepatocellular Carcinoma

Summary: this study enrolls patients who have relapsed/advanced hepatocellular carcinoma (hcc, bclc stage c). the hcc tumor relapsed or metastasized through the body after standard treatment or the patients cannot receive standard treatment under current conditions. this research study uses specific hcc antigens cd8+ t cells, a new experimental treatment. the purpose of this study is to evaluate the safety and tolerance as well as the potential clinical efficacy of an adoptive transfer of cd8+ t cells, sorted with human leukocyte antigen (hla)-peptide multimers and specific for glypican (gpc)-3 /new york esophageal squamous-1 (ny-eso-1) /alpha-fetoprotein (afp) antigens and cultured in vitro, to patients suffering from relapsed/advanced hepatocellular carcinoma (hcc).


Eligibility criteria:
inclusion criteria: * age 18-80 years * patients with relapsed/advanced hcc (bclc, stage c) proved by histopathology or proved by ct or mri imaging system, proven gpc3/ny-eso-1/afp(+), relapsed after previous therapy and no effective therapies known at this time. * life expectancy of ≥ 12 weeks. * wbc\>3.5×10\^9/l, lymph\> 0.8×10\^9/l, hb\>85g/l, plt\>50×10\^9/l, cre\<1.5×the upper limit of normal value. * able to understand and sign the informed consent. exclusion criteria: * any uncontrolled systematic disease: hypertension, heart disease, and et al.; * portal vein tumor thrombus, central nervous system tumor metastasis, or combined with other tumors; * receiving radiochemotherapy, local therapy, or targeting drugs within 4 weeks prior to this treatment; * unstable immune systematic diseases or infectious diseases; * combined with aids or syphilis; * patients with history of stem cell or organ transplantation; * patients with allergic history to related drugs and immunotherapy; * patients with complications associated with liver diseases: moderate or severe pleural effusion, pericardial effusion, ascites, or gastrointestinal hemorrhage; * pregnant or lactating subjects; * unsuitable subjects considered by clinicians.
cancer occurrence and outcome in young patients undergoing cancer treatment at the vanderbilt-ingram cancer center

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific

Summary: rationale: gathering information about the number of young patients with cancer and the outcome of these patients may help doctors learn more about cancer. purpose: this research study is looking at the medical records of young patients undergoing cancer treatment at the vanderbilt-ingram cancer center to determine how often cancer occurs and the outcome of these patients.

objectives: * to determine the number of patients between 15 and 30 years old who are treated for newly diagnosed cancer at the vanderbilt-ingram cancer center (vicc), in middle tennessee, and in the state of tennessee between 1990 and 2005. * to determine the outcomes of these patients. * to determine the number of these patients enrolled on clinical trials at vicc. * to compare the outcomes of these patients when treated on a trial versus not treated on a trial provided they have the same disease. * to compare the number of these patients who are treated on a clinical trial when they are first seen at vanderbilt children's hospital vs vanderbilt university hospital. * to determine referral patterns of these patients to vicc. * to compare the outcomes of these patients who are treated at vicc vs middle tennessee vs the state of tennessee vs the entire nation. * to determine the reason for not enrolling on a clinical trial. outline: cancer cases taken from the vanderbilt-ingram cancer center (vicc) registry and the tennessee cancer registry are examined for number and types of cancer, mortality rates broken down by county and health department region, electronic medical records, and treatment outcomes. data is analyzed for comparison of number of new cancer patients, mortality rates, and referral patterns at vicc versus number of new cancer patients in the region, state, and country.

Eligibility criteria:
disease characteristics: * diagnosis of cancer * newly diagnosed disease from 1990 to 2005 * 15 to 30 years old at the time of cancer diagnosis * must live in the state of tennessee patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific
genotype-phenotype correlation of slc26a4 in ci patients with eva

Conditions: Sensorineural Hearing Loss; Enlarged Vestibular Aqueduct

Summary: to explore the genotype-phenotype correlation of slc26a4 mutations in cochlear-implanted patients with enlarged vestibular aqueduct.

enlarged vestibular aqueduct (eva) is one of the most common forms of inner ear malformation that cause sensorineural hearing loss (snhl). some patients with eva present delayed, fluctuating, and progressive hearing loss, while the others are with congenital or sudden hearing loss. cochlear implants (ci) have been widely used in patients with severe-profound snhl. however, it is difficult to define the optimal timing of ci operations for patients with eva. mutations in slc26a4 are known to be responsible for eva. this study is to explore the genotype-phenotype correlation of slc26a4 mutations in cochlear-implanted patients with eva.

Eligibility criteria:
inclusion criteria: 1. bilateral severe-to-profound sensorineural hearing loss who received cochlear implantation. 2. bilateral or unilateral enlarged vestibular aqueduct (eva) with or without mondini malformation (ip-ii) on temporal bone computed tomography (ct) and/or magnetic resonance imaging (mri). exclusion criteria: 1. hearing loss that is associated with symptoms which meet the criteria of already known syndromes. 2. with other type of inner ear malformation.

Keywords: enlarged vestibular aqueduct slc26a4 cochlear implant
efficacy and safety of combigan® in korean patients with primary open angle glaucoma (poag) and normal tension glaucoma (ntg)

Conditions: Glaucoma, Open-Angle; Normal Tension Glaucoma

Summary: the objective of this study is to evaluate the long-term efficacy and safety of combigan® (brimonidine tartrate/timolol malate) in patients only using combigan® (brimonidine tartrate/timolol malate) and also in patients who require additional iop lowering with lumigan® (bimatoprost) 0.01%.


Eligibility criteria:
inclusion criteria: * patients with primary open angle glaucoma (regardless of intraocular pressure) * previous history of topical beta-blocker use and insufficiently controlled iop exclusion criteria: * pigmentary or exfoliative glaucoma * history of angle-closure or an occludable angle by gonioscopy * prior filtration or laser iridotomy * argon laser trabeculoplasty or selective laser trabeculoplasty performed less than 6 months * history or signs of chronic inflammatory eye disease, ocular trauma, or potentially progressive retinal disease
the relationship between helicobacter pylori infection and inflammatory bowel diseases: a real-life observation

Conditions: Inflammatory Bowel Diseases; Helicobacter Pylori Infection

Summary: numerous epidemiological studies have investigated the association between helicobacter pylori (h. pylori) infection and inflammatory bowel disease (ibd) with various conflicting results. the main objective of this study is to further explore the possible association between h. pylori infection and ibd and its impact on disease course. the investigators sought to conduct a prospective observational study and enroll a total of 182 ibd patients who were screened for h. pylori infection. all the participants will be clinically evaluated at the initial visit and bimonthly for 3 months. several factors will be explored such are diet, physical activity, life style and considering specific environmental exposures that impact the development of disease or its relapse.


Eligibility criteria:
inclusion criteria: * diagnosed with inflammatory bowel disease condition exclusion criteria: * having irritable bowel disease * being younger than 18 years

Keywords: inflammatory bowel diseases helicobacter pylori egypt
interdisciplinary scoliosis correction program.

Conditions: Scoliosis Idiopathic; Scoliosis; Juvenile; Scoliosis; ERAS; Complication,Postoperative; Complication of Surgical Procedure

Summary: the aim of this study is to compare the outcomes after scoliosis surgery before and after the implementation of an interdisciplinary juvenile scoliosis correction program in teenager based on eras (enhanced recovery after surgery) principles.

creating an optimal protocol for interdisciplinary care in the perioperative period in terms of therapeutic management (anesthesia and surgery schedule), as well as care, rehabilitation and ensuring mental well-being determines the real impact on the reduction of the risk of complications in the perioperative period. enhanced recovery after surgery (eras) protocol has been found to result in reduced lenght of stay and complications in adult patients. data in pediatric population remains modest. in addition to eras principles our terapeutic team has created a special educational application for better patient preparation for surgery. the purpose of the application is to explain the general rules of conduct in the process of preparing and carrying out surgery, anesthesia, prehabilitation and physiotherapy in children undergoing orthopedics surgery (e.g. spine surgery for adolescent idiopathic scoliosis). hypothesis: implementing an interdisciplinary juvenile scoliosis correction program based on eras principles and special educational app. will improve patient outcomes leading to a statistically significant reduction in post-operative pain and opioids demand, complication rate, length of stay without increasing readmissions and cost.

Eligibility criteria:
inclusion criteria: * patient with age \< 18 years * patient scheduled for idiopatic scoliosis surgery exclusion criteria: * patient with age \> 18years others type of scoliosis
angiotensin ii in the perioperative management of hypotension in kidney transplant recipients

Conditions: Shock, Surgical; Shock; Hypotension and Shock; Kidney Transplant; Complications; Intraoperative Hypotension; Postoperative Hypotension

Summary: the current standard of catecholamine vasopressor management of perioperative hypotension in kidney transplant patients carries significant risks and falls short in many ways. currently, there is an absence in the scientific literature and research describing the hemodynamic effectiveness and safety of novel pharmacologic agents such as angiotensin ii (giapreza - ang ii) in perioperative kidney transplant patients. phase 3 registration trials have demonstrated the superior safety and efficacy of ang ii (giapreza) in distributive shock patients compared to traditional vasopressor agents and the novel mechanism of action may provide additional protection in renal transplant patients. the pilot study entails giving informed and consenting kidney transplant recipients ang ii (giapreza) as their first vasopressor if the need for vasopressors emerge either intraoperatively or postoperatively in kidney transplant recipients. the primary objective is to evaluate the safety and hemodynamic effects of ang ii (giapreza) in the renal transplant population.


Eligibility criteria:
inclusion criteria: * adult patients \> 18 years of age * receiving deceased donor kidney transplant * pre-transplant ejection fraction (within past 18 months) \> 50% * intraoperative or postoperative distributive shock (according to hospital and study protocol) requiring vasopressor support exclusion criteria: * pregnant patients (they would be excluded from receiving a transplant) * prisoners * history of mesenteric ischemia * history of aortic dissection * history of abdominal aortic aneurysm * allergy to mannitol * absolute neutrophil count \< 1000 cell/mm3 (within past 18 months) * diagnosis of raynaud's phenomenon, systemic sclerosis or vasospastic disease
tolerance to light for patients suffering from keratitis

Conditions: Keratitis

Summary: in order to develop an innovative device to study infectious keratitis, we need to illuminate the cornea of patients suffering from an infectious keratitis with red or near-infrared light. because of technical reasons the shortest possible wavelength (red) presents advantages.

the aim of this preliminary study is to measure the maximal intensity tolerated during illumination with 6 wavelength corresponding : 2 red, 2 far red and 1 near infrared lights in order to determine the shortest wavelength well tolerated by patients, in comparison with the standard blue light illumination.

Eligibility criteria:
inclusion criteria: * social security insurance * suspected infectious keratitis (clinically defined. no lab testing required) * signed informed consent exclusion criteria: * major blepharospasm * aphakia (absence of lens) * pregnant woman * nursing mother

Keywords: keratitis eye infection photophobia red light infrared light
establish the first international database on semi-quantitative values obtained in scintigraphy with datscan® in cadmium-zinc-telluride camera

Conditions: Neurodegenerative Diseases

Summary: datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as parkinson's disease (essential for the differential diagnosis of essential tremor).

datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as parkinson's disease (essential for the differential diagnosis of essential tremor). there are several types of cameras allowing its performance: * conventional anger cameras and, * czt (cadmium-zinc-telluride) semiconductor cameras. at the nancy university hospital, the nuclear medicine department has a wide-field cadmium-zinc-telluride camera: veriton-ct (spectrum dynamics). the interpretation of this examination is purely visual. the objectives are therefore to: * create the first international database of semi-quantitative values in 3d scintigraphy with datscan performed with a veriton-ct camera. * compare this database with another database from a conventional anger camera (lyon nuclear medicine department) to show its superiority.

Eligibility criteria:
inclusion criteria: * adult patients who have undergone a datscan scintigraphy on the veriton camera in the nuclear medicine department of the nancy university hospital and who have an established clinical diagnosis, -absence of neurodegenerative pathology or parkinson's disease or lewy body disease. * the clinical diagnosis can only be established after two years of clinical follow-up. exclusion criteria: * excluded from this research will be the patients opposed to the use of their data, minors, atypical parkinsonian syndromes, * patients who died before two years of clinical follow-up, * patients who had their datscan examination carried out on a camera other than the veriton and - patients lost to follow-up.
efficacy of mindfulness in preventing progression to psychosis in individuals with an ultra high risk for psychosis

Conditions: Clinical High Risk for Psychosis (CHR)

Summary: the main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of uhr (ultra high risk) or fep (first psychotic episode) compared with usual treatment. the secondary objectives were to study the efficacy of a group-based mindfulness intervention: on the reduction of psychotic symptoms; on the maintenance over time (6 months of follow-up) of the efficacy of the intervention on the distress associated with the symptoms of the uhr or pep state; and on various dimensions associated with care: cognitive functions, anxiety, quality of life.


Eligibility criteria:
inclusion criteria: * people aged between 18 and 30 validating the criteria for uhr or pep status on the caarms scale and having a social functional impact (sofas score below 50 or a reduction of more than 30% in the score) exclusion criteria: * previous episode of schizophrenic disorder, schizoaffective disorder or bipolar disorder * previous antipsychotic treatment for more than 12 months * organic mental disorder or intellectual disability * serious suicidal/homicidal risk (but admissible if this risk has been resolved) * insufficient french language skills * adult incapable of giving consent and not under legal protection * protection measure (guardianship/curatorship/court supervision) or under court supervision * person deprived of liberty by judicial or administrative decision (including forced hospitalisation) * persons in a life-threatening emergency * not affiliated to a social security regime

Keywords: psychosis mindfulness
efficacy of a rinse containing sea salt and lysozyme on biofilm and gingival health

Conditions: Chronic Gingivitis; Chronic Gingivitis, Plaque Induced

Summary: this study evaluates the addition of a mouth rinse containing sea salt, xylitol and lysozyme to standardized oral health practices on biofilm formation and gingival health in a group of young adults.

the purpose of this study is to evaluate a new sea salt mouth rinse containing xylitol and the antibacterial enzyme, lysozyme on biofilm formation and gingival health in a group of young adults. xylitol is a well-established non-sugar sweetener and an anti-caries agent. the use of this polyol results in loosely adherent biofilms by reducing the amount of extracellular lipopolysaccharides and lipoteichoic acids, facilitating its easy removal by mechanical means. lysozymes are antibacterial proteins that hydrolyze the linkage between n-acetylmuramic acid and n-acetylglucosamine of peptidoglycan in the cell wall of gram + bacteria effectively limiting growth.

Eligibility criteria:
inclusion criteria: * dentate * medically healthy * no orthodontic bands * an anticipated ability to attend the two scheduled visits exclusion criteria: * significant medical condition (including but not limited to, poorly controlled diabetes mellitus, rheumatic heart disease or clinically significant heart murmur) * pregnancy * recent history of, or ongoing, antibiotic therapy

Keywords: gingival health biofilm formation